Keros Therapeutics (NASDAQ:KROS) Stock Price Down 3.3% – Here’s What Happened

Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price dropped 3.3% on Friday . The stock traded as low as $19.75 and last traded at $19.68. Approximately 13,123 shares changed hands during mid-day trading, a decline of 98% from the average daily volume of 603,857 shares. The stock had previously closed at $20.36.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KROS. Oppenheimer reiterated an “outperform” rating and issued a $27.00 target price (up from $23.00) on shares of Keros Therapeutics in a research note on Wednesday, November 12th. Bank of America boosted their price target on shares of Keros Therapeutics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research note on Friday, November 28th. Zacks Research raised shares of Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. Wedbush increased their target price on shares of Keros Therapeutics from $15.00 to $16.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Finally, TD Cowen upgraded Keros Therapeutics to a “hold” rating in a report on Friday, December 19th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Keros Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $21.38.

Keros Therapeutics Trading Down 6.3%

The stock has a 50-day simple moving average of $18.47 and a 200 day simple moving average of $16.02. The company has a market cap of $581.22 million, a price-to-earnings ratio of 12.36, a PEG ratio of 0.25 and a beta of 0.89.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($1.11) by $0.93. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The company had revenue of $14.26 million for the quarter, compared to the consensus estimate of $4.22 million. During the same quarter in the prior year, the business earned ($1.41) EPS. Keros Therapeutics’s revenue was up 3585.6% on a year-over-year basis. As a group, research analysts forecast that Keros Therapeutics, Inc. will post -4.74 EPS for the current fiscal year.

Insider Buying and Selling

In related news, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of Keros Therapeutics stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total transaction of $95,659,436.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the company’s stock in a transaction dated Wednesday, October 15th. The stock was sold at an average price of $17.75, for a total value of $84,975,125.25. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 20.60% of the company’s stock.

Institutional Investors Weigh In On Keros Therapeutics

A number of institutional investors have recently added to or reduced their stakes in KROS. Western Standard LLC increased its position in Keros Therapeutics by 42.7% during the 3rd quarter. Western Standard LLC now owns 2,189,882 shares of the company’s stock valued at $34,644,000 after buying an additional 654,989 shares in the last quarter. Canada Pension Plan Investment Board purchased a new position in Keros Therapeutics during the second quarter valued at approximately $4,251,000. Caption Management LLC grew its position in Keros Therapeutics by 114.1% during the second quarter. Caption Management LLC now owns 36,078 shares of the company’s stock valued at $482,000 after buying an additional 291,997 shares during the period. Qube Research & Technologies Ltd increased its stake in shares of Keros Therapeutics by 683.7% in the 3rd quarter. Qube Research & Technologies Ltd now owns 303,122 shares of the company’s stock valued at $4,795,000 after purchasing an additional 264,445 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Keros Therapeutics by 38.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 740,606 shares of the company’s stock worth $7,547,000 after buying an additional 205,022 shares during the period. 71.56% of the stock is owned by institutional investors.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.